Balyasny Asset Management
AERI

Balyasny Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Balyasny Asset Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-65,000
Closed -$741K – 2724
2021
Q3 		$741K Buy
+65,000
New +$950K ﹤0.01% 1399

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's AERI Position: Q3 2022 in Review

Balyasny Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 51,816 shares — an estimated $389K sold.

Balyasny Asset Management first reported a position in AERI in Q3 2015 and held it in 10 quarters. The position peaked at $26M in Q2 2018. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • Balyasny Asset Management reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 51,816 Aerie Pharmaceuticals shares in Q3 2022, an estimated $389K.
  • Balyasny Asset Management first reported a position in Aerie Pharmaceuticals in Q3 2015 and held it in 10 quarters.
  • Balyasny Asset Management's Aerie Pharmaceuticals position peaked at $26M in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.